One of the world’s largest drug companies Teva Pharmaceutical Industries, will be working with a start-up company out of Tel Aviv, to market and manufacture the world’s first cannabis inhaler.
The “Syqe Inhaler” is a measured dose inhaler, which would make it so that patients can give themselves more accurate doses of cannabidiol medicine. The dosages would be controlled by the patient’s physician, and an automated mechanism on the inhaler itself.
Dr. Eytan Hyam, Chairman of Syqe Medical, said:
Thanks to the Syqe inhaler, we are effectively moving from cannabis use to cannabis treatment. For doctors, the inhaler solves the problem of prescribing plants for smoking, and offers a solution for patients in that, for the first time, they will be able to receive a precise dose of medical cannabis.
The Syqe inhaler is an important next step in cannabis treatment. It allows for patients to get the treatment that they need, without the stigma that comes with smoking cannabis flower. The inhaler would be easy to use, and discreet as well. The inhaler also reduces the psychoactive effect, so patients would not get high from it.
We’ve reached a new era in medicinal cannabis, from cultivating non-psychoactive strains, to CBD oils. We’ve come a long way from the days of glaucoma patients smoking joints. As doctors and scientists develop new technologies and medicines with cannabis, we may seen the last of the stigma of using cannabis as medicine.